Urine sensors could revolutionize cancer monitoring

NCT ID NCT01693835

Completed Knowledge-focused Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether special sensors could measure certain molecules in urine to track how cancer treatment is working. Researchers collected urine samples from 32 people with metastatic colorectal cancer and healthy volunteers over two days. The goal was to see if these molecules follow daily rhythms that could be used for non-invasive monitoring of cancer therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple, non-invasive urine test to monitor how well cancer therapy is working, reducing the need for frequent biopsies or scans.
What could go wrong: This is a small, early observational study with only 32 participants, so results may not apply to all patients. The approach is still experimental and needs much more testing before it could be used in clinics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER

Contacts and locations

Locations

Paul Brousse Hospital

Villejuif, 94800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.